Original BioMedicals Co., Ltd. (TPEX:6483)
15.60
+0.15 (0.97%)
Feb 11, 2026, 2:59 PM CST
Original BioMedicals Company Description
Original BioMedicals Co., Ltd., engages in the development of new drugs with non-new ingredients in Taiwan.
It develops OBM-A01, for the treatment of acute radiation injury, including nuclear radiation and solar radiation exposed in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; and CCM-CL, a cyclic polypeptide antibiotic.
The company was founded in 2011 and is based in Tainan City, Taiwan.
Original BioMedicals Co., Ltd.
| Country | Taiwan |
| Founded | 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Cliff C. Wang |
Contact Details
Address: No. 9, Nanke 2nd Road Tainan City, 74146 Taiwan | |
| Phone | 886 6 505 5433 |
| Website | i-obm.com |
Stock Details
| Ticker Symbol | 6483 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006483001 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cliff C. Wang Ph.D. | Chief Executive Officer, CRO and Director |
| Lawrence H. T. Tang | Chief Financial Officer |
| Hsiao-Pao Yen | Chief Operating Officer and Director |
| Cai Ling Liao | Accounting Supervisor |
| Duncan Chen MS | Chief Technology Officer and Director |
| Cecilia Hung | Director of Development |
| Dr. Alan Liss Ph.D. | Senior Vice President |
| Gan Xiao Ping | Head of Clinical Research Department |